One Banana Presents Its Sustainability Report 2020
21.7.2021 23:27:00 EEST | Business Wire | Press release
One Banana, the better banana Co., presents its seventh Corporate Sustainability Report reflecting on the achievements and execution of its Sustainability Strategy amid a life-changing year in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005928/en/
Amid a life-changing year, One Banana presents its 7th Corporate Sustainability Report reflecting on the achievements made in the execution of its Sustainability Strategy in 2020. With new projects and continuing existing ones, One Banana aims to promote the well-being of customers, workers, their families, and communities through continuous improvement, environmental conservation, education, health and nutrition projects, among others. (Photo: Business Wire)
"We have taken more time, effort, and resources to prepare and publish our sustainability report due to the implementation of new methodologies to better measure and present how we create sustainable value," said Javier Aguirre, Corporate Director of AgroAmerica. "In this challenging year, we updated the pillars of our Corporate Sustainability Strategy to align business priorities and the changing expectations of our stakeholders."
One Banana and One Banana Ingredients are the brands under which AgroAmerica commercializes bananas and natural ingredients. This year, the corporation consolidated the banana ingredients business, reducing waste to a minimum and offering its customers a new range of sustainable food.
Some outstanding achievements are:
- 186 million bananas transformed into food ingredients under the principle of zero waste.
- Employment generation for 12,537 direct and indirect positions, promoting gender equality and growth opportunities for employees, their families, and communities.
- Responsible use of natural resources through investment in technology that allows a reduction of up to 50% in water use compared to traditional irrigation technologies.
- 11 international certifications, supporting the statement: We strive to achieve sustainable production every day.
- Unprecedented efforts to address the COVID-19 pandemic and extraordinary response to two hurricanes in the Central American region.
- Continuity of existing projects regarding environmental conservation, education, health and nutrition, among other projects to promote the well-being of workers, their families, and communities in the area of influence, as well as support for community management activities.
“We are pleased to present our Sustainability Report to our customers, suppliers, certifying entities, and the general public,” said Fernando Bolaños, CEO of AgroAmerica. “It reflects our commitment to do responsible business and align our corporate management with the Sustainable Development Goals while complying with the Communication on Progress (CoP) before the United Nations Global Compact, an entity of which we have been a signatory since 2020.”
This report reaffirms the corporation’s commitment to producing food and ingredients responsibly and sustainably.
"Our report notes the progress we have made and sets our expectations for the future," said Robert Adams, President of One Banana. "allowing One Banana to be the better banana Co.”,
View full report here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005928/en/
Contact information
Javier Aguirre
Corporate Director
sustainability@agroamerica.com
(502) 2420-9600
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom